Joanne Billings

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19”.

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

New England Journal of Medicine(2020)10.1056/nejmoa2031994

N/A

6.8DataRank · unranked

1924 citations

Thomas F. Patterson, Aneesh K. Mehta, Kay M Tomashek, Cameron R. Wolfe, Varduhi Ghazaryan +55 more

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(21)00384-2

N/A

4.4DataRank · unranked

167 citations

Aneesh K Mehta, Thomas F Patterson, Nathaniel Erdmann, Carlos A Gomez, Mamta K Jain +95 more

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00411-9

N/A

1.9DataRank · unranked

95 citations

Lael M. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, Aaron Trimble +92 more

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(22)00504-5

N/A

1.5DataRank · unranked

67 citations

Gordon MacGregor, Pilar Azevedo, V. Indihar, Claire Keating, Marcus Mall +77 more

SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae198

N/A

0.439DataRank · unranked

13 citations

Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert, Robin Dewar +94 more

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

Annals of the American Thoracic Society(2025)10.1513/annalsats.202507-817oc

N/A

0.396DataRank · unranked

8 citations

T. Spencer Poore, Brandie D. Wagner, Jing Xie, Sonya L. Heltshe, Mary Cross +65 more

22 Effects of elexacaftor-tezacaftor-ivacaftor on antibiotic use in people with cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)00957-8

N/A

0DataRank · unranked

0 citations

Joanne Billings, Hilary McGowan, R. McDevitt, C. McKinzie, W.P. Wilson +2 more

Attitudes toward and preparedness for lung transplantation among individuals with cystic fibrosis in the era of highly effective modulators

BMC Pulmonary Medicine(2024)10.1186/s12890-024-03163-x

N/A

0DataRank · unranked

4 citations

Siddhartha G. Kapnadak, Lauren Bartlett, Oliver J. McElvaney, T. Milinic, Travis Hee Wai +10 more

Predictors of Postacute Sequelae of COVID-19 Development and Rehabilitation: A Retrospective Study

Archives of Physical Medicine and Rehabilitation(2022)10.1016/j.apmr.2022.04.009

N/A

0DataRank · unranked

15 citations

Nicholas E. Ingraham, Nguyen Nguyen, Lianne Siegel, Greg Silverman, Himanshu S. Sahoo +8 more

Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial

The Journal of Infectious Diseases(2021)10.1093/infdis/jiab035

N/A

0DataRank · unranked

3 citations

Abigail R. Gress, Samuel D Libby, Christine E. Ronayne, William E. Matchett, Brooke Noren +6 more